What Is Central Serous Chorioretinopathy?

Central serous chorioretinopathy, often shortened to CSC or CSCR, is an eye condition in which fluid collects beneath the retina at the macula, the small central zone responsible for sharp, detailed vision. It peaks in working-age adults between 40 and 49 years old and affects men roughly three times more often than women. Most first episodes clear on their own within a few months, but the condition has a stubborn tendency to come back, and chronic cases can leave lasting damage to vision even when the fluid eventually disappears.

Who Gets It

A recent global meta-analysis estimated incidence rates per 100,000 person-years at about 48 for people in their thirties, roughly 72 for those aged 40 to 49, about 59 for the 50-to-59 group, and around 36 for people in their sixties. The 40-to-49 bracket carries the highest risk, which makes CSC unusual among retinal diseases; most conditions that threaten the macula become more common with age rather than peaking in midlife.¹

Men are about 2.7 times more likely to develop CSC than women, and they tend to be diagnosed roughly three years younger on average. When women do develop it, their presentation can look different: female patients in one study were significantly older at first presentation (average age around 62 versus 55 for men), had thinner choroids, and showed higher central retinal thickness.² These sex-based differences matter because CSC in older women is more likely to be mistaken for age-related macular degeneration, potentially leading to the wrong treatment approach.

Corticosteroids as a Trigger

If there is one medication class strongly tied to CSC, it is corticosteroids. A case-control study found that about half of CSC patients had a history of steroid use (oral, intravenous, intranasal, or injected into joints), compared with roughly 18% of matched controls, a statistically significant gap.³ The connection is not limited to high-dose regimens. Case reports document CSC appearing within days of starting oral prednisolone at moderate doses and resolving quickly once the drug was tapered.⁴ Patients with autoimmune diseases who need long-term steroids have also shown improvement simply from dose reduction.⁵

The practical takeaway is direct: if you develop CSC while taking any form of corticosteroid, bringing that to your eye doctor’s attention is critical. Inhaled steroids for asthma, nasal sprays for allergies, and steroid creams applied to the skin have all been linked to the condition. Because CSC is one of the few retinal problems that steroids can actually cause rather than treat, the usual medical instinct to use anti-inflammatory steroids for eye problems can backfire here.

Stress and Personality

Doctors have long noticed that CSC patients tend to present during high-stress periods, and the research backs that up. Patients with CSC scored significantly higher on the Social Readjustment Rating Scale, a measure of reactivity to stressful life events, compared to controls.⁶ The proposed pathway goes through the body’s stress-hormone system: elevated sympathetic nervous system activity and glucocorticoid levels may alter blood flow in the choroid and increase the permeability of tiny blood vessels underneath the retina.⁷

A systematic review of personality research over a decade found that stress may interact with personality traits like neuroticism, aggressiveness, and social inhibition to create a cycle: visual symptoms increase anxiety, which raises cortisol, which worsens the eye condition.⁸ This does not mean CSC is “all in your head.” The stress connection runs through hormonal changes that have measurable physical effects on choroidal vessels. But it does help explain why CSC has earned its informal reputation as the “Type A personality” eye disease and why stress management is part of the conversation around recurrence prevention.

Sleep Apnea and Other Risk Factors

The link between obstructive sleep apnea and CSC is one of those areas where the evidence is mixed enough to deserve honest discussion. An early study using sleep-apnea screening questionnaires found that about 59% of CSC patients were at increased risk for sleep apnea, compared with 31% of controls, with a nearly fourfold odds ratio.⁹ A subsequent study using formal sleep testing found sleep apnea in roughly 61% of CSC patients, particularly among men.¹⁰

However, a later matched study using the Berlin Questionnaire found almost no difference between CSC patients and controls, with about 46% of the CSC group and 44% of controls screening positive for sleep apnea risk.¹¹ The honest reading is that sleep apnea may be more common in CSC patients, but the two conditions also share overlapping risk factors (male sex, middle age, higher cortisol levels), so teasing apart a causal link from shared demographics has been difficult. Still, if you have CSC and also snore heavily or feel chronically unrested, mentioning this to your doctor is reasonable.

What Happens Inside the Eye

CSC is defined by a thickened choroid (the blood-vessel-rich layer behind the retina), detachment of the retinal pigment epithelium (the support layer that feeds the retina), and a pocket of fluid beneath the retina itself.¹² The underlying problem starts in the choroid: its blood vessels become abnormally dilated and leaky, which builds up hydrostatic pressure that overwhelms the retinal pigment epithelium’s ability to pump fluid away from the retina. When that pump essentially reverses direction, fluid seeps under the retina and lifts it off its normal position.¹³

A key molecular player in this process is the mineralocorticoid receptor. Aldosterone, a hormone that normally regulates salt and water balance, activates this receptor in choroidal vessels, causing them to dilate and leak. Researchers showed this in animal models and then confirmed it by treating two patients who had chronic, unresolved CSC with eplerenone, a drug that blocks this receptor. Their retinal detachments resolved quickly, and the benefit lasted months after the drug was stopped.¹⁴ That discovery opened up a whole treatment pathway for CSC.

How CSC Is Diagnosed

The classic symptom is a blurry or dim spot in the center of one eye’s vision, sometimes with distortion (straight lines looking wavy) or a subtle shift in color perception. Doctors confirm the diagnosis with imaging rather than symptoms alone. Optical coherence tomography (OCT) is usually the first tool, providing a cross-sectional image that shows the dome of fluid beneath the retina and the thickened choroid. Enhanced depth imaging OCT can measure the choroid’s thickness precisely, which is helpful both for diagnosis and for tracking treatment response.¹⁵

Fluorescein angiography, in which a dye is injected into the arm and photographed as it flows through retinal blood vessels, reveals the specific point where fluid is leaking. In one large series, the most common leakage pattern was an “inkblot” pattern seen in about 53% of patients, with about a third having more than one leakage point. The macula was the most common site, seen in roughly 79% of cases.¹⁶ Indocyanine green angiography, which uses a different dye that highlights the deeper choroidal circulation, can reveal the broader areas of choroidal congestion that fluorescein misses.

Acute Episodes and the Road to Chronicity

Most first episodes of CSC resolve within a few months without treatment. In one study, every patient with acute CSC recovered from their first episode, and none developed persistent fluid leakage during the initial course.¹⁷ But the longer-term picture is less reassuring. Among patients followed for an extended period, about 36% showed increasing damage to the retinal pigment epithelium suggestive of a shift toward chronic disease, and about 23% experienced both ongoing pigment changes and recurrent fluid accumulation.¹⁸

Several factors predict a longer or more stubborn episode. Patients with a very thick choroid (500 micrometers or more beneath the fovea), higher retinal pigment epithelium elevations at the leakage site, and age 40 or older all had independently longer episodes.¹⁹ This matters practically because it helps clinicians decide when to intervene rather than wait. A first episode in a 35-year-old with a moderately thick choroid is often watched for three to four months. A recurrent episode in a 45-year-old with a markedly thick choroid and visible pigment changes may warrant earlier treatment.

Treatment Options

CSC treatment has shifted substantially over the past two decades, moving away from a “wait and see” approach for all patients toward more active intervention, especially for chronic or recurrent disease.

Mineralocorticoid Receptor Antagonists

Oral eplerenone (25 to 50 mg daily) and spironolactone are the most studied medical therapies. A meta-analysis of randomized trials found that mineralocorticoid receptor antagonists significantly improved visual acuity compared to placebo or observation at one and two months, with no patients withdrawing due to side effects and no electrolyte abnormalities.²⁰ However, the reduction in subretinal fluid height was significant at one month but lost statistical significance by two months, suggesting these drugs may work faster on visual function than on fully resolving the fluid.²¹

A randomized crossover study of spironolactone specifically showed a significant reduction in subretinal fluid compared to placebo, along with a measurable decrease in choroidal thickness.²² A review of eplerenone literature found it generally well tolerated and effective, though most studies had small sample sizes and short follow-up periods. Patients with widespread pigment epithelium changes were less likely to benefit, which argues for using these drugs earlier rather than waiting until chronic damage has set in.²³

Photodynamic Therapy

Half-dose (or “safety-enhanced”) photodynamic therapy with verteporfin is considered one of the most effective treatments for chronic CSC. A prospective study found that about 90% of eyes had complete resolution of the fluid pocket by 12 months, with roughly 96% maintaining stable or improved vision.²⁴ The treatment works by reducing the leakiness and congestion of the underlying choroidal vessels. Using a reduced dose of the photosensitizing drug limits the risk of collateral damage to the retina while still addressing the root problem.

Micropulse Laser

Subthreshold micropulse laser therapy has emerged as a gentler alternative to conventional laser photocoagulation. Traditional laser burns the leakage point shut but leaves a permanent scar that can cause a blind spot. Micropulse laser delivers energy in tiny, rapid pulses that stimulate the retinal pigment epithelium to resume pumping fluid without burning through the tissue. In a randomized trial comparing 577-nm micropulse laser to conventional laser, the fluid resolution rates were similar, but micropulse laser caused dramatically less damage to the pigment epithelium: only about 4% of micropulse-treated eyes showed obvious damage, compared with roughly 93% of conventionally treated eyes.²⁵ Another study similarly found equivalent fluid resolution with almost no pigment epithelium damage in the micropulse group.²⁶

Anti-VEGF Injections for Complicated Cases

Anti-VEGF drugs, which are the workhorse treatment for wet macular degeneration, have a narrower role in CSC. They are mainly useful when chronic CSC develops a secondary complication: new, abnormal blood vessels growing under the retina. In those cases, a series of anti-VEGF injections reduced retinal thickness and improved vision, though fluid was still present in about 45% of eyes after treatment.²⁷ An extended course of six injections appeared to produce a more sustained reduction in thickness than the standard three-injection loading dose.²⁸ For uncomplicated CSC without new vessel growth, anti-VEGF injections are generally not the first-line choice.

When New Blood Vessels Grow

One of the most serious complications of chronic CSC is the development of choroidal neovascularization, where abnormal blood vessels sprout from the choroid through the damaged pigment epithelium and grow under the retina. These fragile vessels can leak, bleed, and scar, causing substantial and sometimes permanent vision loss. In one study using advanced imaging, new vessels were found in about 30% of eyes with chronic CSC.²⁹ Independent risk factors for this complication included systemic hypertension, visible pigment changes in the retina, and a specific imaging sign called a “double layer sign” on OCT.³⁰ This complication is a major reason doctors prefer not to leave chronic CSC untreated indefinitely.

Vision After the Fluid Clears

One of the more frustrating aspects of CSC is that vision does not always return to normal even after the fluid is fully absorbed and the retina lies flat again. Patients often describe lingering dimness, subtle distortion, or a vague sense that the previously affected eye “isn’t quite right.” Microperimetry, a test that measures sensitivity at many individual points across the macula, helps explain why. In one study of eyes where CSC had resolved and visual acuity measured a perfect 20/20, macular sensitivity was still significantly lower than in the unaffected eye.³¹

The damage appears to track with structural changes in the retinal pigment epithelium and the photoreceptor layer. Areas where the pigment epithelium looked irregular had markedly lower sensitivity (average about 13 decibels) compared with areas of intact retina (about 18 decibels), and areas where the photoreceptor layer was disrupted were even worse, averaging around 12 decibels.³² This is why retinal specialists increasingly push for treatment of persistent or recurrent CSC rather than simply reassuring patients that it will “go away on its own.” Each episode risks leaving behind a little more permanent damage.

CSC as Part of a Broader Spectrum

Eye specialists now classify CSC as one member of the “pachychoroid spectrum,” a family of conditions that all share the feature of an abnormally thick, congested choroid. The family includes pachychoroid pigment epitheliopathy (a milder precursor state), pachychoroid neovasculopathy (when abnormal vessels grow without classic CSC), and polypoidal choroidal vasculopathy, among others.³³ Recognizing CSC as part of this continuum has changed how specialists think about prognosis. A long-term study comparing outcomes across the spectrum found that CSC and pachychoroid neovasculopathy carried a significantly higher risk of long-term vision loss than the milder entities.³⁴

The Diagnostic Look-Alike That Changes Everything

One clinical scenario with real consequences is the confusion between CSC and Vogt-Koyanagi-Harada (VKH) disease, an autoimmune inflammatory condition that also produces bilateral fluid under the retina. In one comparative study, about 14% of VKH patients were initially misdiagnosed as having CSC, and about 24% of patients with bilateral CSC were first thought to have VKH.³⁵ The stakes of this mix-up are high: VKH requires aggressive corticosteroid treatment, and corticosteroids can severely worsen CSC. Getting the diagnosis wrong means giving a patient a treatment that could make their condition much worse.³⁶ Key distinguishing clues include optic disc redness and leakage (more typical of VKH) and pigment epithelium detachments (more typical of CSC), both of which had high accuracy for their respective diagnoses.³⁷

Genetics Research

The genetics of CSC are still being untangled. Researchers have looked at genes involved in the complement system, which is part of the immune response. A study in an Iranian population found a significant association between a variant in the complement factor H gene (rs3753394) and CSC among people of Persian descent, though another variant in the same gene did not differ between patients and controls.³⁸ Complement factor H is also implicated in age-related macular degeneration, which raises the question of whether the two conditions share some genetic vulnerability even though they differ in mechanism and age of onset. Research in this area is still early, and no genetic test currently guides clinical decisions about CSC risk or treatment. But the complement connection adds another layer to the emerging picture of CSC as a condition driven by multiple overlapping pathways rather than a single cause.